OXURION
Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to better preserve vision in patients with retinal vascular disorders including diabetic macular edema (DME), the leading cause of vision loss in diabetic patients worldwide, as well as other conditions, including wet age-related macular degeneration (AMD) and retinal vein occlusion (RVO).
OXURION
Industry:
Biotechnology Life Science Medical
Founded:
1991-01-01
Address:
Heverlee, Vlaams-Brabant, Belgium
Country:
Belgium
Website Url:
http://www.oxurion.com
Total Employee:
51+
Status:
Active
Contact:
+32 16 75 13 10
Email Addresses:
[email protected]
Total Funding:
137.2 M EUR
Technology used in webpage:
SPF SSL By Default Microsoft Exchange Online Amazon Office 365 Mail Microsoft Microsoft Azure Network Solutions DNS Shutterstock Amazon Ireland Region
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Current Advisors List
Current Employees Featured
Stock Details
Investors List
Epacria Capital Partners
Epacria Capital Partners investment in Post-IPO Equity - Oxurion
Bareldam
Bareldam investment in Post-IPO Equity - Oxurion
Key Employee Changes
| Date | New article |
|---|---|
| 2020-10-14 | Oxurion NV appoints Tom Graney, CFA as Chief Financial Officer |
Official Site Inspections
http://www.oxurion.com Semrush global rank: 3.84 M Semrush visits lastest month: 3.43 K
- Host name: nl1-ts109.a2hosting.com
- IP address: 185.146.22.243
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Oxurion"
Oxurion - Biotech Research Company
Oxurion stands at the forefront of ophthalmic innovation, redefining approaches to treating Geographic Atrophy (GA). While many focus on genetic origins, we explore new horizons through cutting-edge CRISPR-based technology. Our …See details»
Company - Oxurion
Oxurion is a biopharmaceutical company developing next generation therapies, designed to improve and better preserve vision in patients with retinal disorders including Geographic …See details»
Oxurion - Crunchbase Company Profile & Funding
Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to better preserve vision in patients …See details»
Oxurion Avoids Bankruptcy, Announces Board and Management …
Dec 28, 2023 Oxurion NV. Regulated information – Inside information. No bankruptcy filing. Significant reduction in Working Capital costs. Atlas commits to fund Oxurion’s Working …See details»
Oxurion NV (EBR: OXUR) Company Profile & Overview - Stock …
Nov 12, 2024 Oxurion NV Company Description Oxurion NV, a biopharmaceutical company, develops medicines to prevent blindness. It focuses on developing ophthalmic treatments to …See details»
Oxurion NV - LinkedIn
Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 …See details»
Oxurion Company Profile - Office Locations, Competitors ... - Craft
Oct 18, 2024 Oxurion (formerly known as ThromboGenics) is a biopharmaceutical company developing treatments to preserve vision in patients with diseases affecting the back of the …See details»
Oxurion - Org Chart, Teams, Culture & Jobs - The Org
Oxurion (Euronext Brussels: OXUR - formerly known as ThromboGenics) is a biopharmaceutical company developing treatments to preserve vision in patients with diseases affecting the back …See details»
Oxurion's Leadership Team Team - Team members and org chart
The leadership team at Oxurion has a long history of experience in the industry, with a wide range of education and experience. They have been partners at various companies, including the …See details»
Oxurion - Investors
Oxurion is a biopharmaceutical company developing next generation ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including …See details»
Oxurion NV - LinkedIn
Oxurion NV | 7,879 followers on LinkedIn. Advancing Science. Enhancing Vision | Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation …See details»
Oxurion NV Ends Reorganization, Reduces Debt - Nasdaq
Nov 5, 2024 Oxurion NV has successfully terminated its private judicial reorganization procedure after reaching amicable agreements with its key creditors, reducing its debt from €14.7 million …See details»
Oxurion Announces New Strategic Orientation to De-risk and …
Jan 22, 2024 Pascal Ghoson, CEO of Oxurion, states, “Oxurion today lays out its new corporate strategy, which is designed to further diversify and de-risk its ongoing activities. Starting March …See details»
OXURION SUCCESSFULLY RAISES EUR >10 MILLION FROM …
Mar 3, 2022 As a result of the issuance of new shares, Oxurion’s share capital will increase from EUR 56,925,661.32 to EUR 67,331,161.32 and its issued and outstanding shares will increase …See details»
Shareholder Structure & History - Oxurion
May 30, 2006 Oxurion is listed on Euronext Brussels under the symbol OXUR. As of December 4th 2024, Oxurion has a total of 2 567 406 shares outstanding. The table below provides an …See details»
Oxurion NV, OXUR:BRU profile - FT.com - Financial Times
5 days ago Oxurion NV, formerly known as ThromboGenics NV, is a Belgium-based biopharmaceutical company, which focuses on the development and commercialization of …See details»
Oxurion Nv : Oxurion Receives Transparency Notification from …
3 days ago Leuven, BELGIUM – December 4, 2024 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced …See details»
Oxurion NV (OXUR.BR) - Yahoo Finance Canada
Oxurion NV, a biopharmaceutical company, develops medicines to prevent blindness. It focuses on developing ophthalmic treatments to preserve vision for patients with retinal disorders, …See details»
Oxurion Receives Transparency Notification from Atlas Special ...
3 days ago Oxurion received a transparency notification on December 3, 2024, from Atlas Special Opportunities, LLC indicating that as of December 3, 2024, it held 97,098 shares of …See details»
Corporate Governance - Oxurion
Oxurion has adopted a Corporate Governance Charter, based on the Belgian Corporate Governance Code. The purpose of the corporate governance rules is to ensure efficient and …See details»